Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 63

Results For "ET"

10637 News Found

Zydus receives tentative approval from USFDA for Ibrutinib tablets
Drug Approval | July 24, 2025

Zydus receives tentative approval from USFDA for Ibrutinib tablets

Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad


Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs. 1,418 Cr
News | July 24, 2025

Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs. 1,418 Cr

Revenue increased 11.4 per cent to Rs. 8,545 crore


Pfizer completes licensing agreement with 3SBio to expand oncology portfolio
News | July 24, 2025

Pfizer completes licensing agreement with 3SBio to expand oncology portfolio

3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio


Akums launches high-strength Paracetamol oral suspension 500mg/5ml
News | July 23, 2025

Akums launches high-strength Paracetamol oral suspension 500mg/5ml

Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats


Sun Pharma’s phase 3 Cclinical studies for Tildrakizumab 100 mg meet primary endpoint
Clinical Trials | July 21, 2025

Sun Pharma’s phase 3 Cclinical studies for Tildrakizumab 100 mg meet primary endpoint

The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)


Zigly launches its first pet hospital in Mumbai
News | July 18, 2025

Zigly launches its first pet hospital in Mumbai

The new Zigly center features and offers comprehensive veterinary services


Concord Biotech announces successful completion EU GMP inspection at its API facility
News | July 18, 2025

Concord Biotech announces successful completion EU GMP inspection at its API facility

This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance


Lupin launches Loteprednol Etabonate ophthalmic suspension 0.5% in US
News | July 17, 2025

Lupin launches Loteprednol Etabonate ophthalmic suspension 0.5% in US

Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva